SB-300 series (Symic)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameSB-300 series (Symic)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRejection of organ transplantationFibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSymic Biomedical Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSymic Biomedical Inc
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationFibrosis

Other Information

ATC CodeN/A
Related LinksN/A